Blood and Marrow Transplantation Long Term Management. Группа авторов

C, et al. Ancillary therapy and supportive care of chronic graft‐versus‐host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft‐versus‐host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant. 2006; 12:375–396.

      47 47. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002; 288:321–333.

      48 48. Rovó A, Tichelli A, Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Cardiovascular complications in long‐term survivors after allogeneic hematopoietic stem cell transplantation. Semin Hematol. 2012; 49:25–34.

      49 49. Witherspoon RP, Fisher LD, Schoch G, et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. New Engl J Med. 1989; 321:784–789.

      50 50. Witherspoon RP, Deeg HJ, Storb R. Secondary malignancies after marrow transplantation for leukemia or aplastic anemia. Transplantation. 1994; 57:1413–1418.

      51 51. Deeg HJ, Witherspoon RP. Risk factors for the development of secondary malignancies after marrow transplantation. Hematol OncolClin North Am. 1993; 7:417–429.

      52 52. Socié G. Secondary malignancies. Curr Opin Hematol. 1996; 3:466–470.

      53 53. Socié G, Rizzo JD. Second solid tumors: screening and management guidelines in long‐term survivors after allogeneic stem cell transplantation. Semin Hematol. 2012; 49:4–9.

      54 54. Cohen JI. Epstein‐Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine (Baltimore). 1991; 70: 137–60.

      55 55. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi‐institutional study. Blood. 1999; 94:2208–2216.

      56 56. Zutter MM, Durnam DM, Hackman RC, et al. Secondary T‐cell lymphoproliferation after marrow transplantation. Am J Clin Pathol. 1990; 94:714–721.

      57 57. Schouten HC, Hopman AH, Haesevoets AM, Arends JW. Large‐cell anaplastic non‐Hodgkin’s lymphoma originating in donor cells after allogenic bone marrow transplantation. Br J Haematol. 1995; 91:162–166.

      58 58. Meignin V, Devergie A, Brice P, et al. Hodgkin’s disease of donor origin after allogeneic bone marrow transplantation for myelogeneous chronic leukemia. Transplantation. 1998; 65:595–597.

      59 59. Rivet J, Moreau D, Daneshpouy M, et al. T‐cell lymphoma with eosinophilia of donor origin occurring 12 years after allogeneic bone marrow transplantation for myeloma. Transplantation. 2001; 72:965.

      60 60. Rowlings PA, Curtis RE, Passweg JR, et al. Increased incidence of Hodgkin’s disease after allogeneic bone marrow transplantation. J Clin Oncol. 1999; 17:3122–3127.

      61 61. Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. New Engl J Med. 1997; 336:897–904.

      62 62. Bhatia S, Louie AD, Bhatia R, et al. Solid cancers after bone marrow transplantation. J Clin Oncol. 2001; 19:464–471.

      63 63. Socié G, Scieux C, Gluckman E, et al. Squamous cell carcinomas after allogeneic bone marrow transplantation for aplastic anemia: further evidence of a multistep process. Transplantation. 1998; 66:667–670.

      64 64. Daneshpouy M, Socie G, Clavel C, et al. Human papillomavirus infection and anogenital condyloma in bone marrow transplant recipients. Transplantation. 2001; 71:167–169.

      65 65. Curtis RE, Metayer C, Rizzo JD, et al. Impact of chronic GVHD therapy on the development of squamous‐cell cancers after hematopoietic stem‐cell transplantation: an international case‐control study. Blood. 2005; 105:3802–3811.

      66 66. Leisenring W, Friedman DL, Flowers MED, et al. Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol. 2006; 24:1119–1126.

      67 67. Cohen A, Rovelli A, Merlo DF, et al. Risk for secondary thyroid carcinoma after hematopoietic stem‐cell transplantation: an EBMT Late Effects Working Party Study. J Clin Oncol. 2007; 25:2449–2454.